Suppr超能文献

遗传性平滑肌瘤病和肾细胞癌综合征:更新与综述。

Hereditary leiomyomatosis and renal cell cancer syndrome: An update and review.

机构信息

Dermatology, Rutgers New Jersey Medical School, Newark, New Jersey.

Dermatology, Rutgers New Jersey Medical School, Newark, New Jersey; Pathology, Rutgers New Jersey Medical School, Newark, New Jersey; Pediatrics, Rutgers New Jersey Medical School, Newark, New Jersey; Rutgers University School of Public Affairs and Administration, Newark, New Jersey.

出版信息

J Am Acad Dermatol. 2017 Jul;77(1):149-158. doi: 10.1016/j.jaad.2017.01.023. Epub 2017 Mar 14.

Abstract

Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a rare genetic disorder that predisposes individuals to multiple cutaneous leiomyomas, renal cell carcinomas, and in women, uterine leiomyomas. Also known as Reed syndrome, it is caused by a germline heterozygous mutation of the fumarate hydratase tumor suppressor gene. HLRCC is associated with significant morbidity because of pain from cutaneous and uterine leiomyomas, the cutaneous pain often of unique character. Although genetic testing is currently considered the criterion standard to diagnose HLRCC, newer immunohistochemistry markers may provide rapid and cost effective alternatives to genetic testing. Because of the potentially aggressive nature of renal cell carcinomas that develop as early as in childhood, close annual cancer surveillance is desirable in individuals with HLRCC. In this review, we offer an update and an approach to the diagnosis, management, and renal cancer surveillance in HLRCC.

摘要

遗传性平滑肌瘤病和肾细胞癌(HLRCC)综合征是一种罕见的遗传疾病,使个体易患多发性皮肤平滑肌瘤、肾细胞癌,以及女性的子宫平滑肌瘤。也称为里德综合征,它是由延胡索酸水合酶肿瘤抑制基因的种系杂合突变引起的。HLRCC 发病率高,因为皮肤和子宫平滑肌瘤会引起疼痛,而且皮肤疼痛通常具有独特的特征。虽然基因检测目前被认为是诊断 HLRCC 的标准,但新的免疫组织化学标志物可能为基因检测提供快速且具有成本效益的替代方法。由于儿童期就可能发生具有侵袭性的肾细胞癌,因此 HLRCC 患者需要每年进行密切的癌症监测。在这篇综述中,我们提供了 HLRCC 的诊断、管理和肾癌监测的最新信息和方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验